« Back
Home /
BML-286 (Compound 3289-8625)

BML-286 (Compound 3289-8625)

Item no.	DCC-DC67106-100mg
Manufacturer	DCChemicals
CASRN	294891-81-9
Amount	100 mg
Quantity options	100 mg 1 g 250 mg
Category	In Vivo
Applications	IV
Specific against	other
Smiles	C1=CC=C(C=C1)CC(=O)NC2=CC=CC(=C2)C(=O)NC3=CC=CC=C3C(=O)O
Available
Manufacturer - Applications	BML-286 (Compound 3289-8625) is a small molecule inhibitor of the PDZ domain of dishevelled (Dvl) with KD of 10.6 uM, competitively inhibits the Wnt signaling. Compound 3289-8625 (3 uM) inhibits Wnt signaling, effectively reduces luciferase activity by about 2-fold 293 cell line stably transfected with a luciferase reporter. Compound 3289-8625 is cell-permeable and 3289-8625 (10 uM) blocks Wnt signaling in Xenopus, inhibits Wnt pathway responses in culture and in vivo. Compound 3289-8625 suppresses cell proliferation and reduces β-catenin level in prostate cancer PC-3 cells, decreases the levels of β-catenin in both cytosolic fraction and membrane fraction. Compound 3289-8625 sensitized A2780/Taxol cells to paclitaxel.
Molecular Weight	374, 38932

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 100 mg

available

Delivery expected until 12/11/2025

Compare

Add to wishlist

Get an offer

Request delivery time